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Several single nucleotide polymorphism (SNP) genome-wide association studies (GWAS) have
been completed in multiple sclerosis. Follow-up studies of the variants with the most promising
rankings, especially when supplemented by informed candidate gene selection, have proven to be
extremely successful. We report here the results of a multi-stage replication analysis of the
putatively associated SNPs identified in the Wellcome Trust Case-Control Consortium non-
synonymous SNP screen. In total the replication sample consisted of 3444 patients and 2595
controls. A combined analysis of the nsSNP screen and replication data provides evidence
implicating a novel additional locus, rs3748816 in MMEL1 (OR=1.16, p=3.54×10−6) in multiple
sclerosis susceptibility.
Keywords
Multiple Sclerosis; MMEL1; genetics
Introduction
Multiple sclerosis (MS) is considered to be an autoimmune disease of the central nervous
system (CNS) that is characterised pathologically by inflammation, demyelination and
axonal degeneration.1 Epidemiological evidence suggests that it results from unknown
environmental factors acting on genetically susceptible individuals.2; 3
In the last two years the application of high-throughput genotyping methodologies has
resulted in rapid progress in the identification of relevant susceptibility genes in MS. To date
five Single Nucleotide Polymorphism (SNP) Genome-Wide Association Studies (GWAS)
have been performed in MS; four based on indirectly screening common variation through
linkage disequilibrium (LD)4–7 and the fifth based on directly typing non-synonymous
coding SNPs (nsSNPs).8 It is this last study, performed as part of the Wellcome Trust Case
Control Consortium (WTCCC) that has provided the foundation for the work reported here.
Individually none of the five MS GWAS thus far completed succeeded in identifying
statistically unequivocal association at the screening stage (outside the expected association
with the Major Histocompatibility Complex, MHC) although each provides an invaluable
ranking of the variants tested. The extent to which the higher ranges of such rankings are
enriched for genuine associations depends upon the power of the study and the prior odds
that the variants tested are causative, or are in tight LD with such. Follow up studies of the
variants with the most promising rankings, especially when supplemented by informed
candidate gene selection, have proven to be extremely successful in MS. For example, by
extending the typing of a modest number of the most promising variants identified in the
WTCCC nsSNP screen we have already identified association with the tyrosine kinase 2
gene (TYK2) and MS.9 Similar highly focused replication efforts based on GWAS results
have been equally successful in other complex genetic diseases such as celiac disease,10
type I diabetes11 and rheumatoid arthritis.12 In this article we report our most recent efforts
to mine more deeply into the ranking generated in the nsSNP screen.8
Results
A two stage replication effort was employed in this study. In the first stage 1664 of the most
promising markers identified in the nsSNP screen were typed in an independent set of 1038
cases and 1379 controls. These new data were combined with the original data from the
nsSNP screen in order to provide a refined ranking. The results of this extension analysis are
provided in Supplementary Table S1. In stage 2 of our replication effort we chose the 13
most promising SNPs identified from the extension analysis for further investigation in 2406
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cases and 1216 controls. Five SNPs were found to have p < 10−4, however as rs601338 and
rs602662 are in tight LD we only considered rs602662 further (the more strongly
associated). Of the remaining 331 SNPs with a p < 0.05 we chose a further nine SNPs that
were within candidate genes. As one of these SNPs (rs12912505) failed manufacture, in
total we genotyped 12 SNPs.
The results of the 12 SNPs analysed in both replication stages are shown in Table 2 along
with the combined analysis of all available data from the nsSNP screen, stage 1 and stage 2
replication efforts. The population specific results for the top 12 SNPs are shown in
Supplementary Table S2. Using the Breslow-Day test, some evidence for heterogeneity was
shown for one SNP (rs379707). A random effects model was therefore applied for the
analysis of this SNP, though it did not alter the Odds Ratio (OR) (data not shown). In the
combined analysis of all available data, the most significant association was with rs3748816
which lies in the membrane metalloendopeptidase-like 1 gene (MMEL1) (p=3.54×10−6,
OR=1.16, 95% CI=1.09–1.24). The modest power in the second stage limits the extent to
which the evidence for association is increased by this typing. However the result for
rs3748816 remains nominally significant even if corrected for the number of tests performed
in the original screen. A detailed plot of the effect size of this variant within MMEL1 by
country of ascertainment is shown in Figure 1.
Discussion
By systematically extending the analysis of the putatively associated SNPs identified in our
nsSNP GWAS we provide suggestive evidence implicating an additional locus (rs3748816
in MMEL1) involved in MS susceptibility. The SNP rs3748816 is located in exon 15 of
MMEL1 with the protective ancestral “C” allele coding for the polar hydrophilic amino acid
Threonine (ACG) and the risk “T” allele coding a non-polar hydrophobic Methionine
(ATG) at amino acid position 509. This change is predicted to be “probably damaging”
based on the program Polymorphism Phenotyping (PolyPhen). MMEL1, which is also
known as Neprilysin 2 (NEP2), belongs to the M13 family of metalloendopeptidases. Unlike
other members of this family that are ubiquitously expressed, MMEL1 expression is limited
to the testis and CNS. In rodents, the largest isoform is predominantly expressed in testis,
cleavage of this isoform producing a secreted soluble enzyme. The second isoform that is 23
amino acids shorter is a membrane-associated protein highly expressed in the CNS.13 Little
data exists though as to the exact function of the MMEL1 gene. As with other members of
the metalloendopeptidase family, MMEL1 appears to be involved in neuropeptide
degradation,13 and a role in Alzheimer’s disease has also been suggested as it is involved in
the degradation of beta-amyloid.14
The associated SNP lies within a region of extensive LD on chromosome 1 encompassing
the MMEL1 gene and just extending to the tumour necrosis factor receptor superfamily 14
gene (TNFRSF14). A SNP within TNFRSF14 (rs2234167) that lies on the boundary of this
LD block was typed in the first replication stage but did not show any evidence for
significance in the combined analysis of the original nsSNP screen and stage 1 replication
data (p=0.2514). The LD between rs3748816 and rs2234167, as determined from the 4858
individuals that were typed for both markers in stage 1 of the study, is low (D’=1, r2=0.083).
Considerable work will be required to fine map this signal to ascertain if the signal is due to
association with TNFRSF14 or MMEL1.
Two recent GWAS in rheumatoid arthritis (RA) also identified an association with the
MMEL1 gene.12; 15 The SNPs tested in the RA screens (rs3890745 and rs10910099) were
not analysed in the current study. Both SNPs though are in strong LD with rs3748816
(r2=0.962 and 0.924 respectively based on HapMap data) with the major allele increasing
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susceptibility in both of the RA screens and in our study. Growing evidence suggests that
there is an overlap in susceptibility factors between autoimmune diseases,16; 17 yet it
remains to be determined if the association with MMEL1 in MS and RA is due to the same
variant. Further work is required to fully establish the function of this gene and hence its
potential role in MS disease pathogenesis.
A further three markers showed evidence for association in our final analysis with p-values
< 0.001. While the evidence for association is not definitive, further analysis in larger
samples is probably merited for all three markers. The strongest signal of these three
markers was with rs2304497 in the ATP-citrate lyase (ACLY) gene. Rs2304497 lies in exon
4 of ACLY and changes a glutamic acid (Glu) to aspartic acid (Asp) at amino acid position
175, a change that is predicted to be “benign” (polyPhen). ACLY lies within the same LD
block as the promoter for the 2′,3′-cyclic-nucleotide 3′-phosphodiesterase (CNP) gene on
chromosome 17q, a gene which promotes microtubule assembly18 and in mice has been
shown to be essential for axonal survival.19 The next strongest association was with
rs4801853 in the c19orf48 which lies within a gene dense region on chromosome 19q13.33.
In the initial analysis of our nsSNP screen and the stage 1 replication samples, six SNPs
within this region were associated with MS at p <0.05. We only chose the most significantly
associated SNP to study further. Amongst the genes in this region is a cluster of the
kallikrein genes. Kallikreins are a family of serine proteases, of which KLK6 has been
shown to be upregulated in MS plaques20 and both KLK1 and KLK6 have been implicated
in degeneration and disease progression in MS.21 KLK1 and KLK3 have also been
associated with susceptibility to Systemic Lupus Erythematosis (SLE).22 Finally, the
association with the rs930557 marker in the Microcephalin (MCPH1) gene may be the result
of uncorrected population stratification as this SNP is under strong positive selection in
European and Asian populations.23
At the time the WTCCC nsSNP screen was designed an attempt was made to include all
known coding variants, however, the 12,374 SNPs included in the screen represent only a
small fraction of such variants. The tendency for nsSNPs to have a lower allele frequency
also means that even those that have been tested will probably not have been examined to a
level where effects can be excluded. For example, in the combined analysis of our nsSNP
screen and stage 1 replication data, at a 5% risk allele frequency we only have 53% power to
identify a variant with an OR of 1.2 at a p-value < 0.05,24 making it likely that genuinely
associated low frequency variants may have been missed. Furthermore, by screening only
nsSNPs, other variations that may be involved in disease such as intronic or copy number
variations will not have been captured. As with other genuine associations seen in complex
genetic diseases, the associated variants we have identified in this and other studies have a
relatively limited effect on an individual’s risk, but together the growing number of
validated associations is helping to build a greater understanding of the mechanisms of
disease pathogenesis.
In summary, we have found suggestive evidence for an association with rs3748816 in the
MMEL1 gene. Independent replication and functional analysis will be necessary to fully
confirm this locus as a genuine susceptibility gene in MS.
Materials and Methods
Samples
The first replication stage included subjects recruited through the University of Cambridge,
UK; Brigham and Women’s Hospital in Boston, USA; and the University of California San
Francisco, USA. Healthy unrelated controls were also included from both US sites and from
the 1958 birth cohort in the UK. Controls were selected in order to optimise the matching of
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gender and age. The second replication stage included additional samples recruited through
the University of Cambridge, UK; John Hunter Hospital Newcastle, Australia; and the
University of Eastern Piedmont, Novara Italy. All samples were collected with informed
written consent and appropriate local ethical approval. All patients satisfied recognised
clinical criteria for the diagnosis of MS.25; 26 Subjects were chosen with all four main types
of MS and varying disability. Full demographic features are provided in Table 1. The
individuals included in the original WTCCC non-synonymous screen are described
elsewhere.8
Markers
In the original WTCCC nsSNP screen a carefully developed set of over 15,000 nsSNPs were
typed in five UK DNA sets: controls from the 1958 birth cohort (1958BC) and patient
samples from individuals with MS, ankylosing spondylitis (AS), autoimmune thyroid
disease (ATD) and breast cancer (BC). After the application of stringent quality control the
primary MS specific component of the analysis (MS vs 1958BC) yielded reliable data from
12,374 SNPs in up to 975 MS cases and 1466 controls. Two additional analyses were
conducted using data from the other conditions considered in the project on the basis that for
most variants these samples would represent reasonable “controls” in an analysis of
susceptibility to MS. In the first of these additional analyses the MS data was compared with
that from all other samples considered (MS vs 1958BC+AS+AITD+BC) and in the second
(an “immune” based analysis) the three autoimmune conditions were compared with the
non-autoimmune samples (MS+AS+AITD vs 1958BC+BC). We used the following criteria
to select markers for inclusion in our current follow-up effort:
1. P-value ranked within the top 1% of any of the three MS relevant analyses (n=303).
2. Having p<0.1 in both the main nsSNP analysis (MS vs 1958BC) and in the parallel
screen performed by the International Multiple Sclerosis Genetics Consortium
(IMSGC)4 (n=99). This obviously only applied to those variants that were included
in both studies.
3. Any marker with a minor allele frequency of >5% and p<0.2 in the main nsSNP
analysis (MS vs 1958BC) (n=1506).
After excluding the 18 SNPs we had previously investigated 9 these criteria identified a total
of 1908 SNPs worthy of further follow up, of which 1853 were successfully genotyped.
Following the application of stringent quality control measures (see below), 1664 of these
gave reliable data.
Genotyping/Quality Control - stage 1
Genotyping was performed using the Illumina Infinium 60K BeadChip platform.27 The
Illumina Infinium protocol involves amplification of genomic DNA, fragmentation of this
DNA, hybridization of the DNA on the BeadChip, extension on the BeadChip, and imaging
to read the chip. Samples were excluded if the genotyping efficiency was low (<95%).
Similarly SNPs were excluded if the genotyping success rate was <95% or there was
evidence of significant deviation from Hardy-Weinberg equilibrium (HWE) (p<0.001).
Genotyping/Quality Control - stage 2
The 13 SNPs considered in stage 2 of the replication were genotyped using TaqMan®
Assays-On-Demand (Applied Biosystems). One of the SNPs however failed in the
manufacturing process (rs12912505) so in total 12 SNPs were analysed. Genotyping was
completed on a 7900 Sequence Detection System and plots generated and analysed using
Sequence Detection System Software v2.1. All 12 SNPs fulfilled quality control
requirements with a genotyping success rate >95% and Hardy-Weinberg equilibrium
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p>0.001. In this stage samples were excluded if the genotyping success was <50%. This
resulted in the exclusion of a total of 48 samples, 14 from the Italian dataset (2 cases, 12
controls) and 34 from the UK dataset (15 cases, 19 controls) which resulted in the final
analysis of a total of 2406 cases and 1216 controls in the second stage replication effort.
Statistical analysis
Data quality checking and statistical analysis was completed using PLINK v 1.05. As the
results of several populations were combined, we analysed the data using a Cochran-Mantel-
Haenzel test treating each population as a separate stratum and tested for heterogeneity
between populations using the Breslow-Day statistic (see Table 2).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Odds ratio for the rs3744816(T) allele in MMEL1
The area of the box is proportional to the number of cases included in the study. The error
bars indicate the 95% confidence intervals. The population specific odds ratios are shown
for reference.
Ban et al. Page 8
Genes Immun. Author manuscript; available in PMC 2011 June 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Ban et al. Page 9
Ta
bl
e 
1
D
em
og
ra
ph
ic
 fe
at
ur
es
 o
f a
ffe
ct
ed
 in
di
vi
du
al
s
Sa
m
pl
es
C
as
es
C
on
tr
ol
s
A
ve
ra
ge
 A
ge
a
t O
ns
et
ED
SS
 %
D
ise
as
e 
C
ou
rs
e %
<
3
3 
to
 <
6
≥6
U
nk
n
R
R
SP
PP
PR
U
nk
n
W
TC
CC
 n
sS
N
P 
sc
re
en
97
5
14
66
30
.3
27
.2
24
.3
48
.1
0.
4
54
.6
32
.0
13
.0
0.
0
0.
4
Re
pl
ic
at
io
n 
St
ag
e 1
10
38
13
79
U
K
1
36
9
76
4
32
.3
35
.8
17
.6
43
.6
3.
0
54
.2
26
.3
15
.5
0.
0
3.
8
U
S
66
9
61
5
33
.9
53
.0
23
.8
23
.3
0
49
.9
17
.9
10
.2
3.
0
19
.0
Re
pl
ic
at
io
n 
St
ag
e 2
24
06
12
16
A
us
tra
lia
15
9
12
0
34
.4
33
.8
38
.9
26
.8
0.
6
63
.9
18
.4
5.
1
2.
5
10
.1
Ita
ly
82
9
63
5
32
.5
47
.1
25
.2
16
.6
11
.2
69
.0
11
.3
8.
7
1.
4
9.
6
U
K
2
14
18
46
1
30
.0
28
.2
27
.3
42
.5
2.
0
57
.9
31
.0
8.
8
0.
0
2.
3
ED
SS
 =
 E
xp
an
de
d 
D
isa
bi
lit
y 
St
at
us
 S
ca
le
; R
R 
= 
Re
la
ps
e 
Re
m
itt
in
g;
 S
P 
= 
Se
co
nd
ar
y 
Pr
og
re
ss
iv
e;
 P
P 
= 
Pr
im
ar
y 
Pr
og
re
ss
iv
e;
 P
R 
– 
Pr
og
re
ss
iv
e 
Re
la
ps
in
g;
 U
nk
n 
= 
U
nk
no
w
n
Genes Immun. Author manuscript; available in PMC 2011 June 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Ban et al. Page 10
Ta
bl
e 
2
R
es
ul
ts 
fro
m
 th
e 
re
pl
ic
at
io
n 
an
al
ys
is 
of
 th
e 
m
os
t p
ro
m
isi
ng
 1
2 
SN
Ps
SN
P
Lo
cu
s
C
hr
R
isk
A
lle
le
W
TC
C
C
n
sS
N
P
Sc
re
en
a
R
ep
lic
at
io
n
St
ag
e1
b
R
ep
lic
at
io
n
St
ag
e 2
c
R
ep
lic
at
io
n
A
na
ly
sis
C
om
bi
ne
d
C
om
bi
ne
d 
A
na
ly
sis
d
R
A
F
C
as
e
R
A
F
C
on
tr
ol
Br
es
lo
w
D
ay
 T
es
t
p-
va
lu
e
p-
va
lu
e
p-
va
lu
e
p-
va
lu
e
p-
va
lu
e
O
dd
s R
at
io
 (C
I 9
5%
)
p-
va
lu
e
rs
37
48
81
6
M
M
EL
1
1
T
1.
63
×1
0−
3
1.
34
×1
0−
3
0.
01
78
3.
57
×1
0−
4
3.
54
×1
0−
6
1.
16
 (1
.09
–1
.24
)
0.
69
6
0.
66
0
0.
65
0
rs
23
04
49
7
A
CL
Y
17
A
0.
01
87
9.
40
×1
0−
4
0.
38
9
1.
11
×1
0−
3
9.
76
×1
0−
5
1.
21
 (1
.10
–1
.33
)
0.
89
8
0.
87
7
0.
54
0
rs
48
01
85
3
C1
9o
rf4
8
19
C
3.
18
×1
0−
3
0.
01
30
0.
07
44
3.
24
×1
0−
3
1.
13
×1
0−
4
1.
14
 (1
.07
–1
.22
)
0.
74
1
0.
71
2
0.
63
4
rs
93
05
57
M
CP
H1
8
G
4.
64
×1
0−
3
0.
39
5
0.
25
4
0.
02
79
5.
87
×1
0−
4
1.
15
 (1
.06
–1
.24
)
0.
20
3
0.
18
1
0.
29
2
rs
60
26
62
FU
T2
19
C
0.
01
51
6.
95
×1
0−
4
0.
73
8
0.
02
29
1.
40
×1
0−
3
1.
10
 (1
.04
–1
.17
)
0.
49
3
0.
46
7
0.
68
1
rs
20
43
21
1
CA
RD
8
19
T
0.
15
14
0.
05
92
0.
16
0
0.
03
11
0.
01
11
1.
09
 (1
.02
–1
.16
)
0.
33
2
0.
31
4
0.
74
2
rs
20
66
80
7
ST
AT
2-
IL
23
A
12
C
0.
05
83
0.
06
37
0.
64
0
0.
10
7
0.
01
87
1.
16
 (1
.03
–1
.31
)
0.
94
1
0.
93
1
0.
34
4
rs
10
48
99
90
CD
20
7
2
A
3.
43
×1
0−
3
0.
04
61
0.
40
0
0.
46
0
0.
03
40
1.
07
 (1
.01
–1
.14
)
0.
36
3
0.
34
7
0.
08
45
rs
20
34
31
0
CD
30
0L
F
17
T
0.
02
23
0.
02
46
0.
53
2
0.
19
7
0.
04
44
1.
09
 (1
.00
–1
.18
)
0.
17
6
0.
16
6
0.
28
5
rs
40
40
1
IL
3
5
A
0.
15
3
0.
02
39
0.
46
5
0.
28
0
0.
08
27
1.
07
 (0
.99
–1
.15
)
0.
22
3
0.
21
3
0.
22
7
rs
22
90
61
0
IL
5R
A
3
A
0.
09
90
0.
05
87
0.
03
69
0.
83
4
0.
42
3
1.
03
 (0
.96
–1
.09
)
0.
63
7
0.
63
4
0.
05
11
rs
37
97
07
FY
B
5
T
0.
02
57
0.
16
9
0.
01
63
0.
45
8
0.
69
7
1.
01
 (0
.95
–1
.08
)
0.
69
6
0.
69
5
0.
00
74
1
Ch
r =
 c
hr
om
os
om
e;
 R
A
F 
= 
ris
k 
al
le
le
 fr
eq
ue
nc
y
R
es
ul
ts 
sh
ow
n 
in
 b
ol
d 
ar
e 
in
 th
e 
op
po
sit
e 
di
re
ct
io
n 
to
 th
e 
as
so
ci
at
io
n 
id
en
tif
ie
d 
in
 th
e 
W
TC
CC
 n
sS
N
P 
sc
re
en
a T
he
 W
TC
CC
 n
sS
N
P 
sc
re
en
 in
cl
ud
ed
 9
75
 ca
se
s a
nd
 1
46
6 
co
nt
ro
ls 
fro
m
 th
e U
K
 p
op
ul
at
io
n
b R
ep
lic
at
io
n 
St
ag
e 
1 
in
cl
ud
es
 a
 to
ta
l o
f 1
03
8 
ca
se
s a
nd
 1
37
9 
co
nt
ro
ls 
fro
m
 th
e U
K
 an
d 
U
S 
po
pu
la
tio
n
c R
ep
lic
at
io
n 
St
ag
e 
2 
in
cl
ud
es
 a
 to
ta
l o
f 2
40
6 
ca
se
s a
nd
 1
21
6 
co
nt
ro
ls 
fro
m
 th
e A
us
tra
lia
, I
ta
ly
 an
d 
th
e U
K
 p
op
ul
at
io
n
d T
he
 c
om
bi
ne
d 
an
al
ys
is 
in
cl
ud
es
 a
ll 
da
ta
 fr
om
 th
e 
W
TC
CC
 n
sS
N
P 
sc
re
en
, r
ep
lic
at
io
n 
sta
ge
 1
 a
nd
 re
pl
ic
at
io
n 
sta
ge
 2
Genes Immun. Author manuscript; available in PMC 2011 June 1.
